BLIS K12® Found to Support Oral Hygiene, Reducing the Severity of Halitosis

Dunedin, New Zealand and Saint Charles, MO USA – Blis Technologies and Stratum Nutrition announce a new clinical study on the effects of oral-cavity probiotic, BLIS K12® (Streptococcus salivarius K12), on the reduction of halitosis in children.  The study was published in Oral Health & Preventive Dentistry (http://www.ncbi.nlm.nih.gov/pubmed/27508274) and supports previous research showing BLIS K12’s benefits for oral malodor,

[Burton et al (2006) J Appl Microbiol 100:754-764].

This randomized, controlled clinical trial was conducted by Jamali et al (Faculty of Dentistry, Tabriz University of Medical Sciences) on 208 male and female children between the ages of 6 and 9 years and exhibiting mild-to-strong oral malodor, as recorded by experienced examiners. The children did not have compromised oral health, and were otherwise healthy.

The children were divided into four groups (n=52 each), with each group assigned a designated degree of oral hygiene: Group A, conventional (brushing/flossing) oral hygiene (COH); Group B, COH plus tongue scraping (TS); Group C, COH,TS plus chlorhexidine wash (CHX); Group D, COH, TS, CHX, plus BLIS K12 probiotic (1 slow-dissolving tablet daily containing >1 x 109 colony forming units). Malodor was assessed using the organoleptic test (OLT), considered as the gold standard for measuring bad breath. The OLT assessment was taken for all groups at one week and three months after the initiation of the interventions.

The investigators reported that children in Group D demonstrated superior OLT scores at the 1-week (vs Groups A and B; P<0.001) and 3-month (vs Groups A, B, and C; P˜0.02) follow-up examinations. Group D had a clinically meaningful number of participants (78%) showing major and moderate levels of improvement in OLT scores, compared to Groups A (20%), B (43%) and C (45%) at the 3-month follow-up. Overall, parental satisfaction regarding their child’s halitosis was 91% for Group D, which reflected an approximate 96% subject response rate (slight-to-major improvements in OLT score). This study is consistent with earlier research performed in adults, and supports the consideration of S. salivarius K12 following oral disinfection as a complimentary approach for longer-term control of oral malodor.

Dr. Joseph L. Evans, Executive Manager Research & Development, Stratum Nutrition, comments on the study:  “Using the gold standard assessment of oral malodor, a study design that more closely approximates real-world protocols recommended by dentists, and a clinically meaningful group size, the investigators have found that add-on supplementation with BLIS K12® significantly reduced oral malodor, to varying degrees, in virtually every child. While a broad-spectrum, anti-bacterial mouthwash might exhibit a short-term benefit for oral malodor in selected individuals, chronic use is not recommended as it increases the risk of side effects, likely alters the composition of the oral bacterial microbiome, and apparently loses efficacy, as reported in this study.”

BLIS K12® is a unique strain of Streptococcus salivarius, a bacterial species commonly found in the oral cavity of healthy individuals. Supporting a beneficial microbiome in the oral cavity through BLIS K12® supplementation can be one of the best ways to maintain continued optimal oral hygiene and upper respiratory health. For more information on this study and others, please contact Dr. Joseph Evans at Joseph.Evans@StratumNutrition.com.

 

Citation: Jamali Z, Aminabadi N A, Samiei M, Deljavan A S, Shokravi M and Shirazi S. (2016) Impact of Chlorhexidine Pretreatment Followed by Probiotic Streptococcus salivarius Strain K12 on Halitosis in Children: A Randomised Controlled Clinical Trial. Oral Health & Preventive Dentistry, 14(4):305-313. http://www.ncbi.nlm.nih.gov/pubmed/27508274

 

About Blis Technologies
Blis Technologies is the manufacturer of oral probiotic products based on the natural human mouth bacterium Streptococcus salivariusStratum Nutrition is the exclusive North American distributor of BLIS probiotic products including BLIS K12 and BLIS M18.  BLIS K12® is a probiotic member of the bacterial species Streptococcus salivarius developed in Dunedin, New Zealand for the support of oral and upper respiratory health. Visit Stratum Nutrition’s website for more information on BLIS K12®.

 

Launch of Mythocondro, the Non-Animal Chondroitin Sulfate

Supply Side West is approaching and Gnosis will be protagonist with the launch of Mythocondro®, the first Non-Animal Chondroitin sulfate of fermentation origin, that promises to change completely the CS industry.

Gnosis offers the unique opportunity to discover the scientific steps forward of the product, by participating to the speech organized by Gnosis in the Education Session of the VENDORBRIEF Presentation.

The speech will be held Thursday, October 6th, 1:00-1:50 pm at SSW, BaysideHall D, Booth WW111 and will be led by Prof. Nicola Volpi, Associate Professor of Biochemistry, University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy, one of the global leading expert in chondroitin.

The speech will show the concerns about quality, reproducibility and safety of chondroitin sulfate animal derived and present the PATENTED NEW NON-ANIMAL CHONDROITIN SULFATE characterized by:

  • Produced by fermentative processes: non-animal production
  • High purity and quality profile guaranteed by controlled, reliable and reproducible controlled process
  • Very low protein content and a substantial absence of unusually sulfated and over-sulfated disaccharides
  • Demonstrated biological activity and established safety with published results
  • Low molecular weight and enhanced bioavailability

mythocondro supplyside west 2016 mythocondro supplyside west 2016-2

Ubiquinol and its Effect on Energy Levels

Ever wondered why you may be feeling tired? You could be suffering from a lack of Ubiquinol in the body. Ubiquinol provides every cell in the body with energy so that it can function and is also a powerful antioxidant.

FYTEXIA enters sports nutrition with 4 new ingredients, all supported by human studies.

French supplier FYTEXIA will kick-off SupplySide West 2016 with a Grand Opening ceremony built around the release of an entirely new line of branded, clinically proven ingredients for sports nutrition.

The aim of the FYTEXIA is to bringing out the vast – and mostly unexploited – potential of natural polyphenols for the optimization of physical activity. Under the leadership of Dr Julien Cases, Head of Innovation and Scientific Affairs, FYTEXIA investigated specific combinations of bioactives from fruit and vegetables and their demonstrable benefits for the active consumer. Through this research, Cases’s team created 3 innovative ingredients for key,
existing market categories, as well as a breakthrough solution to address a new and growing demand:

PerfLoad® – a performance-enhancing system based on extracts of grape, pomegranate, and green tea.
BurnToRun® – a combination of citrus fruits, L-carnitine, and guarana seeds to increase endurance capacity.
TensLess® – a recovery accelerator composed of elderberry, mangosteen and pomegranate fruit extracts.
HolisFiit® – a solution to maximize the body-mind benefits of wellness-oriented activities such as yoga or Pilates.

FYTEXIA’s decision to initiate these innovation projects was triggered not only by sports nutrition’s fast-growing revenues, but also by the extension of its consumer base from hardcore bodybuilders to everyday fitness enthusiasts. With the market evolving into the mainstream, brands willing to sustainably occupy the new space must create products suited for mainstream exposure. In other words, formulas must be perfectly safe, supported by strong
human evidence, and made of non-GMO ingredients that people can recognize and trust.

Fruit and vegetable polyphenols can combine all those aspects – if sourced properly and if investigated through well-designed clinical research. Using its expertise in this area, FYTEXIA enacted a strategic plan to simultaneously deliver 4 ingredients as a diversified and consistent new line offering each fitness enthusiasts and athletes the ideal support for their workout.

SupplySide West 2016 will mark the completion of the development work, with a launch supported not only by the Grand Opening ceremony and a large booth presence, but also by an entirely redesigned graphic identity for FYTEXIA’s marketing materials.

New investors, new growth ambitions
The launch of FYTEXIA’s new sports nutrition line will take place just a few months after the company completed a new round of investment with French venture capital fund ArchiMed. ArchiMed, Europe’s first independent private equity healthcare specialist, acquired stake in FYTEXIA in June 2016, allowing the company to make the best of its potential as a worldwide industry leader in clinically-proven fruit and vegetable polyphenol ingredients.

According to Lionel Schmitt, President at FYTEXIA, “FYTEXIA has demonstrated outstanding growth over the past 4 years. In this context, we share with Archimed the same vision and ambition for the company and aim at speeding up our development by leveraging our science platform and our international setup to take the company into the next level”. For more details, please contact FYTEXIA at contact@fytexia.com.

New study confirms NEM Brand Eggshell Membrane is an Effective Joint Treatment for Man’s Best Friend

Carthage, MO USA – Stratum Nutrition and joint-venture partner, ESM Technologies, the manufacturer of innovative, commercialized eggshell and eggshell membrane wellness ingredients, are pleased to announce a new canine study has published in the journal, Veterinary Medicine: Research & Reports, evaluating their joint health ingredient, NEM® brand eggshell membrane.

This 6-week, multi-center, randomized, double-blind, placebo-controlled trial was conducted at eight different veterinary clinics to evaluate NEM’s efficacy, safety and tolerability in the treatment of sub-optimal joint function in dogs. Fifty-one privately-owned dogs having mild to moderate persistent sub-optimal joint function (e.g. difficulty in getting up from a laying position, a noticeable limp, impaired gait, difficulty in climbing stairs, etc.) received either oral NEM®, 6 mg/lb. (~13.5 mg/kg) or placebo once daily for 6 weeks. Changes in joint function, joint pain, and quality of life in the NEM® group versus the placebo group were evaluated by both dog owners and veterinarians via either the validated Canine Brief Pain Inventory (CBPI) (owner assessment, 1 week & 6 weeks) or Veterinary Canine Scoring Assessments (VCSA) (veterinarian assessments, 6 weeks). Additionally, changes in serum levels of the cartilage degradation biomarker, CTX-II, were also evaluated at 6 weeks.

Results showed that supplementation with NEM® significantly reduced joint pain and improved joint function rapidly (CBPI 1-week) and demonstrated a lasting improvement in joint pain (VCSA 6-week) leading to an improved quality of life (CBPI 6-week). Moreover, a profound chondroprotective effect was demonstrated following 6 weeks of supplementation with NEM® (CTX-II). There were also clinically meaningful results from a brief responder analysis, demonstrating that a significant proportion of treated dogs will benefit substantially from NEM® supplementation. The results of this peer-reviewed study were recently published online (https://dx.doi.org/10.2147/VMRR.S101842).

“This canine study on NEM® provides further evidence supporting NEM’s ability to modify symptoms of pain, and it provides an alternative to the use of pharmaceuticals which have known detrimental side effects,” mentioned Kenneth J. Kopp, DVM, the lead veterinarian for the trial.

Kevin J. Ruff Ph.D., MBA, CCRP – Sr. Director of Scientific & Regulatory Affairs for Stratum Nutrition – also commented on the study, “With so many dogs suffering from sub-optimal joint function, it’s important for dog-owners to have safe and effective treatment options like NEM®. It was particularly gratifying to learn of the chondroprotective effect in this study, as we believe this to be the first of its kind in naturally-occurring joint disease in dogs.”

For more information about this published study on NEM®, please visit StratumNutrition.com.

About Stratum Nutrition and ESM Technologies
Stratum Nutrition, a Novus International Business, is Empowering Product Innovation through functional and specialty ingredients for manufacturers and marketers of foods, beverages and supplementation. Stratum offers a portfolio of branded, value-added ingredients that are progressive, safe and reliable. These ingredients are based on consumer need, supported by science and the backing of a trusted multinational company. ESM Technologies is the manufacturer of eggshell calcium and eggshell membrane wellness ingredients: ESC® and NEM®. The company researches, develops and manufactures high-quality branded ingredients from a traceable and sustainable supply of eggshells from USDA-inspected facilities. More information about Stratum Nutrition HERE.

Chemi Nutra Files Novel Patent Application For Alpha-GPC Specialty Ingredient

Chemi Nutra announces the filing of a novel patent related to its proprietary AlphaSize® Alpha-Glyceryl Phosphoryl Choline (A-GPC) and its use in replacing, displacing, or augmenting caffeine and providing superior physiological benefits, without caffeine’s detrimental mental and physical effects.

Scott Hagerman, president of Chemi Nutra said, “This patent filing demonstrates Chemi’s commitment to the nutritional supplement and beverage industries, and is supported by research studies that collectively demonstrate how our branded, natural, full GRAS, AlphaSize® A-GPC functional ingredients truly impact human performance – both mental and physical”.

Documented, published, scientific substantiation exists to support significant health benefits for AlphaSize® A-GPC, which can improve all memory related abilities, reaction, agility, explosive power output, jumping, and running. AlphaSize® A-GPC is a fully functional ingredient, as it provides real energy for mind and body and not just a temporary effect with jitteriness and crash. It is tasteless, odorless, and stable, hence, is ideal for all dietary supplements, functional beverages, and functional foods, which target mental energy, sports nutrition, and healthy aging.

The FDA acknowledged Generally Recognized as Safe (GRAS) status on AlphaSize® A-GPC, (granting it GRN 000419) with an Agency Response Letter, affirming utmost safety for its use in a wide range of conventional foods and beverages.

A-GPC is a safe, natural, and rapidly absorbed form of choline, that has been shown to raise free plasma choline levels much faster than other choline precursors. A-GPC is a proven, powerful precursor of acetylcholine, the body’s primary neurotransmitter, which is involved in all brain functions and, importantly, also in agility and muscular contraction functions.

Chemi Nutra is the U.S. business unit of parent company Chemi S.p.A., a privately held pharmaceutical and nutraceutical company based in Milan, Italy. Chemi, with cGMP certified manufacturing facilities in Italy and Brazil, is best known in the global nutritional arena for its introduction of phosphatidylserine (PS), the popular dietary supplement which has been granted two qualified health claims by the FDA, and is used to enhance learning, memory, and concentration, improve exercise performance, impact youthful wellbeing, and reduce stress.

XYIENCE Protein Bars the First to Feature Sustamine L-Alanyl-L-Glutamine

Protein-Packed Bars Also Help with Hydration, Recovery*

New York City – XYIENCE® has released XYIENCE Protein Bars, the first such products to contain Sustamine® L-Alanyl-L-Glutamine.

The non-GMO, gluten-free XYIENCE Protein Bars are designed to fuel the body with the cleanest ingredients to provide sustained energy during workouts. They contain 20g of Protein with only 1 gram of Sugar, sweetened with Stevia and are soy free containing 15-17g Fiber made with Quinoa and Amaranth and also with Sustamine, a dipeptide of 2 amino acids that help the body with Hydration and sustaining physical performance!

Sustamine® L-Alanyl-L-Glutamine, a dipeptide of glutamine, provides several substantial benefits such as enhanced recovery, immune system support, and performance. On top of these benefits, research suggests that Sustamine® is absorbed more than 200 percent better than standard L-glutamine.

Muscles must be hydrated and engorged with glycogen. And when it’s all over, the body needs to recover. Sustamine® – a form of glutamine, the most abundant single amino acid in the body – provides essential support during times when the body undergoes large amounts of stress – like during intense weightlifting or dealing with the challenges of everyday life.*

XYIENCE Protein Bars come in three great tasting flavors: Chocolate Peanut Butter, Chocolate Mint and Chocolate Crunch. For more information and to purchase online, click here.

XYIENCE Protein Bars

About XYIENCE (pronounced zi-ence)
Launched in 2006 and now headquartered in Austin, Texas, XYIENCE is the original zero calorie energy beverage with all natural flavors and colors. XYIENCE is available in eight exclusively zero calorie flavors: Cherry Lime, Mango Guava, Frostberry Blast, Blue Pomegranate, Cran Razz, Fruit Punch, Tangerine and Melon Mayhem. XYIENCE is marketed strictly to consumers ages 18 and over. XYIENCE was acquired by Big Red, Inc. in 2014. Find more info about XYIENCE online at www.XYIENCE.com or at a retailer near you.

XYIENCE® is a registered trademark by XYIENCE BEVERAGE COMPANY, LLC, in AUSTIN, TX, 78730.

About Sustamine® L-Alanyl-L-Glutamine
Sustamine® L-Alanyl-L-Glutamine, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and patented form of L-Alanyl-L-Glutamine. Sustamine is a stable dipeptide of L-Alanine and L-Glutamine and is more easily absorbed by the body than complex protein molecules. This makes Sustamine a highly effective ingredient for hydration, endurance and recovery.* Sustamine is manufactured through a patented fermentation process to yield high quality and high purity. Vegetarian, allergen-free and the only GRAS L-Alanyl-L-Glutamine, Sustamine is also tasteless, odorless, and stable in liquids. For more information on Sustamine, visit: www.sustamine.com.
Sustamine® is a registered trademark of Kyowa Hakko Bio Co., Ltd.

About Kyowa Hakko USA
Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Lumistor® L-Hydroxyproline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine® L-Alanyl-L-Glutamine. For more information, visit www.kyowa-usa.com.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

1 Up Nutrition Doubles Down and Introduces HIIT Aminos with Cognizin Citicoline and Sustamine L-Alanyl-L-Glutamine

Supplement Formulated for High-Intensity Interval Training

New York City – HIIT Aminos, a new product from 1 Up Nutrition, takes reinvigorating the body after a tough workout to new extremes – times two.

The dietary powder supplement contains both Cognizin® Citicoline and Sustamine® L-Alanyl-L-Glutamine to not only assist muscle recovery, but also help the brain stay focused during intense exercise. HIIT Aminos provides a blend of amino acids – including Cognizin® and Sustamine® – to promote growth, protein synthesis, performance and strength.*

Sustamine® is combined with L-Glutamine, L-Leucine, L-Isoleucine and L-Valine in a 5,025mg per serving recovery amino acid blend. Sustamine® supports rehydration, energy replenishment and muscle recovery.* It helps deliver the endurance needed to cover long-distance performance.*

A 605mg per serving energy and focus blend is anchored by Cognizin®, a branded form of citicoline, an essential substance for brain health. Citicoline works to enhance communication between neurons, maintain normal levels of acetylcholine, protect neural structures, and enhance health brain activity and energy.*

The powders come in two flavors: Passion Fruit and Kiwi & Strawberry. For more information about HIIT Aminos, click here.

1 Up Nutrition HIIT Aminos - PF 1-Up-Nutrition-HIIT-Aminos-KS

About 1 Up Nutrition
1 UP Nutrition is dedicated to the pursuit of optimum performance and nutrition by providing an elite and versatile range of all natural supplements to both professional athletes and the general public alike. We strive to support our customers’ fitness and competitive goals with high quality products with the purest ingredients. With our core values of integrity, communication and perseverance, we are determined to empower our customers by taking the time to provide specifically tailored specialist advice and feedback to help them build the perfect supplement stack for their individual health goals. Self-optimization is more than a hobby; it’s a way of life and always remember that everything starts with great nutrition and exercise. For more information, visit www.1upnutrition.com.

About Cognizin® Citicoline
Cognizin® Citicoline, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and patented form of Citicoline, a natural substance found in every cell of the body and especially vital to brain health.* Citicoline is a potent brain-health nutrient. A proprietary form of citicoline, Cognizin® has been clinically studied to support mental energy, focus, attention and recall. Cognizin is manufactured through a patented fermentation process to yield high quality and high purity. Cognizin is also highly stable, GRAS, ultra-pure and allergen-free. For more information on Cognizin, visit www.cognizin.com.

About Sustamine® L-Alanyl-L-Glutamine
Sustamine® L-Alanyl-L-Glutamine, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and patented form of L-Alanyl-L-Glutamine. Sustamine is a stable dipeptide of L-Alanine and L-Glutamine and is more easily absorbed by the body than complex protein molecules. This makes Sustamine a highly effective ingredient for hydration, endurance and recovery.* Sustamine is manufactured through a patented fermentation process to yield high quality and high purity. Vegetarian, allergen-free and the only GRAS L-Alanyl-L-Glutamine, Sustamine is also tasteless, odorless, and stable in liquids. For more information on Sustamine, visit: www.sustamine.com.

About Kyowa Hakko USA
Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Lumistor® L-Hydroxyproline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine® L-Alanyl-L-Glutamine. For more information, visit www.kyowa-usa.com.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Kyowa Expert Shares Views on Dipeptide Applications, Benefits of Glutathione at Nutritional Summit

Dr. Toshikazu Kamiya Highlights New Fermentation Technologies

Singapore – Ingredient manufacturers are discovering unique ways to create nutraceutical values using innovative fermentation technologies.

That was the message shared by Dr. Toshikazu Kamiya at the recent Nutraceutical and Functional Food Asia Pacific Summit in Singapore. Dr. Kamiya, research fellow for Kyowa Hakko Bio, talked on how amino acids, peptides and oligosaccharides are being leveraged for better nutraceutical values.

Dr KamiyaDr. Kamiya shared recent findings on the health benefits of oral glutathione supplementation. Specifically, he discussed how Kyowa’s Setria® Glutathione has been shown to replenish the body’s reserves, which may be depleted by poor lifestyle choices, natural aging and stress.* The fermentation process, he said, is the key to creating glutathione that is high purity and high quality.*

“As the most abundant antioxidant in the human body, glutathione is critical to the protection and overall health of organs and cells,” Dr. Kamiya said. “Glutathione already is used in many nutraceutical applications, including those for skin whitening and liver protection. It shows great promise for continued development and application in nutraceutical formulations.”

The presentation also covered the physical property of dipeptides and their applications. Kyowa manufactures Sustamine® L-Alanyl-L-Glutamine, a dipeptide of alanine and glutamine, which has superior solubility and stability in water as compared to.* Again, fermentation is what makes dipeptides like Sustamine® effective in enhancing recovery, building immune support and increasing metabolic rates.*

“Kyowa Hakko Bio uses a proprietary dipeptide fermentation technology to produce L-Alanyl-L-Glutamine from glucose,” he said. “The end product – Sustamine® – is water soluble, making it a perfect ingredient for sports nutrition drinks, powders and supplements. It also has clinical applications for rehydration, as well as parenteral and enteral nutrition.”

Dr. Kamiya also spoke on the use of amino acids for wound healing and the functional roles of oligosaccharides. His presentation was part of the larger NFFAP Summit, held in early July. The conference provides information on “authoritative interpretation on market entry and supervision regulations for functional food in the main Asia-Pacific region.”

About Setria® Glutathione
Setria® Glutathione, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and patented form of glutathione that, when taken orally1, has been shown to replenish the body’s reserves, which may be depleted as a result of poor lifestyle choices, stress or natural aging. Called the “master antioxidant,” glutathione helps protect cells in the body from the damaging effects of oxidative stress and toxins. Setria® Glutathione is manufactured through a patented fermentation process to yield high purity and high quality, is vegetarian and allergen-free. For more information about Setria® Glutathione, visit www.SetriaGlutathione.com.

About Sustamine® L-Alanyl-L-Glutamine
Sustamine® L-Alanyl-L-Glutamine, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and patented form of L-Alanyl-L-Glutamine. Sustamine is a stable dipeptide of L-Alanine and L-Glutamine and is more easily absorbed by the body than complex protein molecules. This makes Sustamine a highly effective ingredient for hydration, endurance and recovery.* Sustamine is manufactured through a patented fermentation process to yield high quality and high purity. Vegetarian, allergen-free and the only GRAS L-Alanyl-L-Glutamine, Sustamine is also tasteless, odorless, and stable in liquids. For more information on Sustamine, visit: www.sustamine.com.

About Kyowa Hakko Bio Singapore
KYOWA HAKKO BIO SINGAPORE PTE LTD is the Southeast Asia office for KYOWA HAKKO BIO an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine® L-Alanyl-L-Glutamine. For more information visit http://www.kyowahakko-bio.co.jp/english/ or email singapore@kyowa-asia.com

About Kyowa Hakko Bio
KYOWA HAKKO BIO employs leading-edge fermentation technology to develop innovative manufacturing processes for producing various useful substances and is offering ingredients ranging from amino acids, nucleic acid-related compounds, vitamins, organic acids to oligosaccharides and dipeptides globally to customers in the pharmaceutical, nutrition and healthcare markets. Our primary objective is to organically integrate fermentation and synthesis by fully leveraging the fundamental technological capabilities, human resources and assets we have developed and perfected since pioneering the method to manufacture Glutamic Acid by fermentation over 50 years ago. For more information, visit http://www.kyowahakko-bio.co.jp/english/.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Forthcoming launch of Mythocondro

The Non-Animal Chondroitin Sulfate for joint benefits

According to EULAR (the European league against rheumatism)

[1, 2], OARSI (osteoarthritis research society international) [3] and World Health Organization (WHO) [4], the musculoskeletal or rheumatic diseases are the major cause of morbidity throughout the world, having a substantial influence on health and quality of life, also causing an enormous burden of cost on health systems. Osteoarthritis (OA) is an important example of the more than 150 conditions and syndromes with the common denominators of pain and inflammation. 40% of people over the age of 70 years suffer from osteoarthritis of the knee, 80% of patients with osteoarthritis have some degrees of limitation of movement, and 25% cannot perform their major activities of daily living [4].

Chondroitin sulfate (CS), a basic natural component of cartilage and synovial fluid, is used to help to reduce the risk of Osteoarthritis, the risk of joint degeneration and the risk of cartilage deterioration [5].

CS, like other natural polysaccharides, is today derived from animal sources by extraction and purification processes [6]. As a consequence, source material, manufacturing processes, the presence of contaminants and many other factors contribute to the quality, structure and physico-chemical properties of the final product and of the overall biological and pharmacological actions of these agents. The industrial production of CS uses animal tissue sources as raw material, derived from different species of animals. Actually it generally relies on bovine, porcine, chicken or cartilaginous fish such as sharks and skate by-products, in particular cartilage, as raw material [7, 8]. More important, a mix of all these sources are possible producing a CS final product having mixed characteristics and not well identified activities.

The potential consumer safety and quality problems associated with the use of animal-derived CS, suitable for pharmaceutical and nutraceutical applications, have historically prompted the search for an alternative source.

The new ingredient, branded as Mythocondro®, is the first CS obtained with a fermentation-based manufacturing process followed by a chemical selective sulfation. The result of this innovative approach is a non-animal CS with homogeneous structure and the presence of sulfate groups in defined positions, a constant charge density and molecular mass parameters.

Mythocondro® warrants high purity, clear identity profile, batch-to-batch reproducibility, established safety with an astounding very low content of proteins and other (macro)molecules, as well as biological activity.

Mythocondro® promises to change completely the CS industry providing a reliable and reproducible source of product. Furthermore it is the first chondroitin sulfate suitable for vegetarians and free from restrictions of use related to religious and supply issues.

Mythocondro® solves any concerns related to origin of the production, the possible presence of transmissible infective agents, the contamination and adulterations typical of animal-derived raw materials.

Mythocondro® has five patents based upon scientific advances in the biotechnological areas ((PCT/EP2012/058654; US 8,609,394; US 8,771,992; US 8,664,196; EP217004; EP2852437; JP577036; PCT/EP2014/051308).

Of course, the non-extractive origin guarantees:

  • Homogeneous structure and physico-chemical properties
  • High purity
  • Very low content of proteins
  • No presence of virus and/or prions
  • Highly and point-by-point controlled production process for highly controlled and reproducible final product

Mythocondro® has been extensively studied in order to evaluate its characteristics, safety profile and efficacy (Miraglia et all. Food Chem Toxicol 2016; 93: 89-101.) Pre-clinical and clinical studies have been carried out demonstrating superior biological activity versus animal-derived CS both in vitro and in vitro. (Bauerova et all. Pharmacology 2014; 94: 109-14.)

Mythocondro® will be officially launched at the next Supply Side West, where those attending the Trade Show in Las Vegas will have a unique opportunity to discover the scientific steps forward of the product by participating to the speech organized by Gnosis in the Education Session of the VENDORBRIEF Presentation. The speech will be led by Prof. Nicola Volpi, Associate Professor of Biochemistry, University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy, one of the global leading expert in chondroitin.

For more information contact marketing@gnosis-bio.com

References:

  1. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-55.
  2. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 377-88.
  3. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Ost Cartil 2010; 18: 476-99.
  4. WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium, The burden of musculoskeletal conditions at the start of the new millennium. World Health Organization Technical Report Series, 2003. 919: p. i-x, 1-218, back cover.
  5. Martel-Pelletier J, Boileau C, Pelletier JP, et al. Cartilage in normal and osteoarthritis conditions. Clin Rheumatol 2008; 22: 351-84.
  6. N (Ed). 2006. Chondroitin sulfate: structure, role and pharmacological activity. Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo: Academic Press.
  7. Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol 2009; 61: 1271-80.
  8. Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci 2007; 96: 3168-80.